America Pays Twice as Much for Healthcare and Dies Sooner: Where the Money Goes, What It Buys, and Why Nobody Agrees on the Fix

The United States spent $14,885 per person on healthcare in 2024, equal to 17.2% of GDP [1]. The next highest spender among OECD nations, Switzerland, spent roughly $8,000 [1]. The OECD average was $5,967 [1]. American life expectancy in 2023 was 78.4 years—2.7 years below the OECD average of 81.1 [2]. Japan, spending roughly a quarter of what the US spends per capita, achieved a life expectancy of 84.0 years [3].

This is the central puzzle of American healthcare: the world's most expensive system produces outcomes that trail those of nations spending far less. The reasons are contested, the proposed solutions are politically explosive, and the data—when examined honestly—is uncomfortable for both sides.

Source: World Bank Health Expenditure Data

Data as of Mar 20, 2026CSV

The Spending Gap in Numbers

World Bank data shows the US has spent more than any peer nation every year for at least a decade, and the gap is widening [3]. In 2023, the US spent $13,473 per capita, compared to $6,395 in Germany, $6,187 in Canada, $5,407 in the UK, $5,149 in France, and $3,638 in Japan [3]. As a share of GDP, US health spending at 17.2% dwarfs Germany's 12.7%, France's 12.1%, and the UK's 11.3% [1].

Where the money goes is the first question that divides analysts. A 2024 JAMA study found that higher US spending is driven primarily by higher prices—not higher use of services [4]. Americans do not visit doctors more often, are not hospitalized more frequently, and do not consume more prescription drugs by volume than citizens of peer nations. They simply pay more for each unit of care.

Three categories absorb most of the excess:

Administrative costs account for roughly 8% of US healthcare spending, compared to 1–3% in peer countries [5]. When insurer and provider administrative burdens are combined, they represent approximately 30% of excess US spending compared to comparable nations [6]. The multi-payer system requires billing departments, prior authorization staff, claims processing, and coding specialists that single-payer systems largely eliminate.

Pharmaceutical prices in the US are 2.78 times higher than in comparison countries across all drugs, and 3.22 times higher for brand-name drugs even after adjusting for rebates [7]. US drug spending per capita was $1,443 in the most recent comparison year, versus $939 in Switzerland and an average of $749 across 11 peer nations [7].

Specialist and hospital prices round out the picture. An MRI in the US costs several times what it costs in Germany or France. A hip replacement costs roughly double. Physician salaries, particularly for specialists, far exceed those in peer nations [5].

The Outcomes Deficit

Source: World Bank Infant Mortality Data

Data as of Mar 20, 2026CSV

The US infant mortality rate stands at 5.5 per 1,000 live births as of 2023, versus an OECD average of 4.2 [2]. Japan's rate is 1.8; Germany's 3.1; France's 3.4 [3]. The US ranks 32nd out of 38 OECD countries [2].

Maternal mortality tells an even starker story. The US rate was 18.6 deaths per 100,000 births in 2023 [8]. For Black women, it was 50.3—more than three times the rate for white women (14.5) and nearly five times the rate for Asian women (10.7) [8]. No comparable nation approaches these numbers.

Preventable deaths—those from conditions treatable with timely, effective healthcare—are markedly higher in the US. A 2023 Commonwealth Fund analysis found the US had the highest rate of mortality amenable to healthcare among 11 high-income countries studied [9].

What Americans Get for the Money—and What They Don't

The financial harm Americans absorb from their healthcare system has no parallel in the developed world. At least $220 billion in medical debt is owed by US residents [10]. Roughly 41% of Americans carry some form of medical debt [10]. An estimated 66.5% of personal bankruptcy filings cite medical bills as the primary cause, translating to approximately 550,000 bankruptcies per year [11]. In 2024, an estimated 31 million Americans borrowed money to pay for healthcare [12].

The 2024 uninsured rate held at approximately 8%, or 27.1 million people, propped up by enhanced ACA marketplace subsidies set to expire at the end of 2025 [13]. Without congressional action to extend those subsidies, 22 million marketplace enrollees face average premium increases of 114% starting in 2026 [13].

Census data shows that across age groups, millions of Americans lack coverage: approximately 4.2 million children and young adults under 19, 9.4 million adults ages 19–34, 12.1 million ages 35–64, and nearly 480,000 seniors 65 and older lack insurance [14]. People who lose jobs frequently lose coverage during the transition—a feature unique to the US employer-sponsored insurance model.

No other wealthy nation has a comparable phenomenon. Medical bankruptcy is essentially nonexistent in Canada, the UK, Germany, France, and Japan, because out-of-pocket exposure is either capped by law or eliminated by universal coverage [11].

Where the US System Outperforms

The strongest case for the US system rests on three pillars: cancer care, innovation, and specialist access.

The American Action Forum, a center-right policy institute, has documented that the US achieves a nearly 70% all-cancer five-year survival rate, compared to 55% in the UK and 57% in Spain [15]. For specific cancers—breast, prostate, colorectal—the US consistently ranks at or near the top globally. This is not a trivial advantage. For the millions of Americans diagnosed with cancer each year, higher survival odds are a concrete, life-and-death benefit.

Access to specialists and advanced procedures is faster in the US for those with insurance. Wait times for elective surgery, diagnostic imaging, and specialist consultations are generally shorter than in Canada or the UK [15]. The US produces a disproportionate share of medical innovation: new drugs, medical devices, surgical techniques, and clinical research originate in the US at higher rates than its population share would predict.

The critical caveat, raised by researchers at the Commonwealth Fund and elsewhere, is that these advantages are not equally distributed [9]. Cancer survival rates are substantially better for insured Americans with access to comprehensive care. For the uninsured or underinsured, cancer outcomes are worse—sometimes dramatically so. The US system's advantages are concentrated among those who can afford to access it.

The Case Against Single-Payer: Wait Times, Rationing, and Real Costs

Advocates for the current US model—or for market-based reforms rather than single-payer systems—point to documented problems in countries with government-run healthcare.

In Canada, the evidence is substantial. According to SecondStreet.org, 23,746 Canadians died while on waitlists for surgeries or diagnostic procedures in the 2024–2025 fiscal year [16]. Since April 2018, more than 100,000 Canadians have died while waiting for care [16]. The median wait time from GP referral to treatment has grown from 9.3 weeks in 1993 to 30 weeks in 2024 [16].

An estimated 105,529 Canadians sought medical treatment outside the country in 2025, including over 10,000 for general surgery [17]. A March 2024 Ipsos poll found that 42% of Canadians said they would travel to the US and pay out of pocket for routine care if needed [17].

The UK's National Health Service faces parallel challenges. In December 2024, only 71.3% of cancer patients received their first treatment within the 62-day target from urgent referral—well below the 85% standard [18]. The NHS reported its worst-ever cancer treatment waiting times in 2023 [18].

These are not abstract policy debates. They represent real patients experiencing real delays with real consequences. Critics of single-payer systems argue that trading financial barriers for time barriers does not obviously improve welfare—it simply shifts who suffers and how.

The Case for Systemic Change: Price Controls and Administrative Savings

Proponents of single-payer or heavily regulated multi-payer systems (like Germany's) argue that the mechanisms behind better outcomes per dollar in peer nations are well-documented.

Price regulation is the most direct lever. Every peer nation negotiates or sets prices for pharmaceuticals and medical procedures. The US, until recently, did not. The Inflation Reduction Act of 2022 gave Medicare limited drug price negotiation authority for the first time, and a May 2025 executive order directed HHS to pursue "most-favored-nation" pricing that would benchmark US drug prices to those paid abroad [19]. Whether these measures will meaningfully close the gap remains to be seen.

Administrative simplification from a unified payment system would reduce the 8% of spending consumed by administration toward the 1–3% range seen in peer nations [5]. The CBO estimated in 2022 that single-payer systems could reduce administrative costs by approximately 1.8% of GDP by 2030 [20].

Stronger primary care is a consistent feature of higher-performing systems. The US spends less on primary care as a share of total health spending than peer nations, despite spending far more overall [21]. A 2025 Milbank Memorial Fund scorecard described the state of US primary care as a "cost of neglect," linking underinvestment in frontline medicine to worse management of chronic disease and higher downstream costs [21].

Different approaches to end-of-life care also play a role. The US spends a disproportionate share of healthcare dollars in the final months of life compared to peer nations, with aggressive interventions that often extend suffering without meaningfully extending life [22].

Source: World Bank Life Expectancy Data

Data as of Mar 20, 2026CSV

How Much Is the Healthcare System vs. Everything Else?

A persistent counterargument—advanced most forcefully by conservative health policy analysts—holds that America's poor health outcomes are primarily driven by non-healthcare factors: obesity, gun violence, drug overdoses, car accidents, and income inequality.

The data partially supports this. The US obesity rate is 35%, nearly double the OECD average of 19% [23]. Researchers have calculated that obesity alone reduces US life expectancy by approximately 1.7 years [24]. The US motor vehicle death rate of 13.3 per 100,000 is six times the UK's 2.2 per 100,000 [24]. Firearms remained the leading cause of death among American children for the third consecutive year in 2023 [25]. Drug overdose deaths—driven by the opioid and fentanyl crisis—have no parallel in peer nations.

If these factors were removed from the comparison, the US outcome gap would narrow significantly but would not disappear. Research published by Our World in Data found that even when controlling for external causes of death (homicide, accidents, overdoses), the US still underperforms peer nations in life expectancy [24]. Chronic disease management, preventive care access, and healthcare-amenable mortality remain worse in the US even after adjusting for behavioral and social factors.

This matters because it means neither side has a clean narrative. The US healthcare system is not solely responsible for America's health outcomes—but it is not absolved, either. A complete account must hold both truths simultaneously.

The Racial Disparity Dimension

The aggregate numbers obscure a critical feature of US healthcare: outcomes vary enormously by race and income. Black infant mortality (10.9 per 1,000 live births) is 3.1 times higher than Asian infant mortality (3.5) [2]. Black maternal mortality (50.3 per 100,000) is more than triple the white rate [8].

These disparities reflect both healthcare access gaps and broader social determinants of health—housing, nutrition, environmental exposure, chronic stress. They also mean that comparisons between the US and peer nations are comparing averages that mask profound internal inequality. For affluent, insured Americans, health outcomes are comparable to the best in the world. For poor and minority Americans, outcomes resemble those of middle-income countries.

What Would a Transition Actually Cost?

The CBO's 2022 analysis of five illustrative single-payer systems projected that federal health subsidies in 2030 would increase by $1.5 trillion to $3.0 trillion compared to current law [20]. However, total national health expenditures would change by amounts ranging from a decrease of $700 billion to an increase of $300 billion—meaning that depending on design choices, a single-payer system could cost the nation less in total even as federal spending rises [20].

The job displacement concern is real but bounded. Approximately 1.8 million workers in health insurance administration and billing could be displaced [26]. The Economic Policy Institute argues this would be offset by increased demand for healthcare workers (an estimated 2.3 million full-time-equivalent positions) as coverage expands to the currently uninsured and underinsured [26].

State-level experiments offer mixed lessons. Massachusetts's 2006 reform (the model for the ACA) successfully expanded coverage but did not control costs. Vermont attempted to implement a single-payer system in 2011 but abandoned the effort in 2014 when projected tax increases proved politically unacceptable—an 11.5% payroll tax and a sliding-scale income tax of up to 9.5% [20].

The honest assessment: a well-designed single-payer system could reduce total national health spending while expanding coverage, but it would require tax increases that are politically difficult, would disrupt an industry employing millions, and would face implementation risks that state-level experiments have not resolved.

The Path Forward Is Unclear—and That's the Honest Answer

The US healthcare spending-outcomes paradox has no clean resolution because it reflects genuinely competing values. Americans who prioritize choice, speed, and innovation point to real advantages of the current system—advantages that would be at risk in a transition to government-run care. Americans who prioritize universal access and financial protection point to real suffering under the current system—suffering that is absent in every peer nation.

The data does not support the claim that the US system works well. It does not support the claim that single-payer systems are without serious costs. Both of these statements are true, and any honest policy discussion must start from that uncomfortable foundation.

What the data does show clearly: the US pays far more than any comparable nation and gets worse aggregate outcomes. The excess spending is driven by prices, not use. The financial burden on individuals is uniquely harsh. And the advantages the system does deliver—principally in cancer care and specialist access—are concentrated among those with the means to access them.

Whether that is an acceptable arrangement is not a question the data can answer. It is a question for the public.